Glofitamab for mantle cell lymphoma that returned after CAR-T
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have mantle cell lymphoma that came back after or didn’t respond to your last treatment
- You must have already had a type of immunotherapy called CAR-T cell therapy, and also tried or couldn’t take a targeted therapy called a BTK inhibitor
- You must have at least one measurable tumor (about the size of a grape or larger) on a CT scan
- You must be 18 years or older
- You must have adequate organ function (kidney, liver, blood counts) as shown by recent blood tests
- You must agree to use effective birth control if you or your partner can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This trial tests a new drug called glofitamab for people with mantle cell lymphoma (MCL) whose cancer did not respond or came back after CAR T-cell therapy. Glofitamab is a type of immunotherapy that helps your immune system fight the cancer.
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
This trial adds glofitamab, a new targeted drug, to standard chemotherapy for people with untreated mantle cell lymphoma. The goal is to see if the combination works better than chemo alone.
This trial tests a drug called glofitamab, which helps your immune system attack lymphoma cells. It is for people with aggressive B-cell lymphoma that has grown after standard treatments. The study uses a biopsy to tailor the treatment during therapy.
Hear when a new Recurrent Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.